Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Hendlisz, Alain ^a   Golfinopoulos, Vassilis ^a   Deleporte, Amelie ^a   Paesmans, Marianne ^a   Mansy, Hazem El ^a   Garcia, Camilo ^a   Peeters, Marc ^b   Annemans, Lieven ^c   Vandeputte, Caroline ^a   Maetens, Marion ^a   Borbath, Ivan ^d   Dresse, Damien ^e   Houbiers, Ghislain ^f   Fried, Michael ^g   Awada, Ahmad ^a   Piccart, Martine ^a   Laethem, Jean Luc Van ^h   Flamen, Patrick ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f Service d'Oncologie et d'Hématologie   (Belgium)

^g ZiekenhuisNetwerk Antwerpen   (Belgium)

^h ERASME HOSPITAL   (Belgium)

Author keywords

Adjuvant; Chemosensitivity; Colon cancer; Early assessment; FDG PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; ONCOLOGY; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BELGIUM; COLONIC NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GENETICS; MORTALITY; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR EMBOLISM;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; FOLLOW-UP STUDIES; GENE REARRANGEMENT; HUMANS; LEUCOVORIN; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84877068204     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-190     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay, Pisani P. Global cancer statistics. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. American Joint Committee on Cancer (AJCC) AJCC Cancer Staging Manual 2009, New York: Springer, Edge SB, Byrd DR, Carducci MA, 7, American Joint Committee on Cancer (AJCC).
3. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80:30-36. 10.1093/jnci/80.1.30, 3276901.
4. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. 10.1056/NEJMoa032709, 15175436.
5. Chau I, Cunningham D. Adjuvant therapy in colon cancer-what, when and how?. Annals of Oncol 2006, 17:1347-1359.
6. Lenihan DJ, Cardinale DM. Late Cardiac Effects of Cancer Treatment. J Clin Oncol 2012, Sep 24. [Epub ahead of print].
7. Ahles TA, Root JC, Ryan EL. Cancer- and Cancer Treatment-Associated Cognitive Change: An Update on the State of the Science. J Clin Oncol 2012, Sep 24. [Epub ahead of print].
8. Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 2012, 30(29):3578-3587. 10.1200/JCO.2011.39.5640, 22927526.
9. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. J Clin Oncol 2012, [Epub ahead of print].
10. Miller AB, Hogestraeten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214. 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6, 7459811.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
13. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18 F] fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006, 24:5366-5372. 10.1200/JCO.2006.05.7406, 17088570.
14. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006, 107:2678-2687. 10.1002/cncr.22276, 17063502.
15. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M. Impact of [18 F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High-Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 2012, Oct 29. [Epub ahead of print].
16. Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18 F-FDG PET/CT. J Nucl Med 2007, 48:744-751. 10.2967/jnumed.106.038513, 17475962.
17. Schaake EE, Kappers I, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers JA, van Tinteren H, Klomp HM. Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol 2012, 30:2731-2738. 10.1200/JCO.2011.39.4882, 22753915.
18. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006, 24:4692-4698. 10.1200/JCO.2006.06.7801, 16966684.
19. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007, 8:797-805. 10.1016/S1470-2045(07)70244-9, 17693134.
20. Zum Büschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ. 18 F-FDG PET-Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial. J Nucl Med 2011, 52:1189-1196. 10.2967/jnumed.110.085803, 21764790.
21. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ, Oyen WJ. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008, 19:348-352. 10.1093/annonc/mdm470, 17962202.
22. Byström P, Berglund A, Garske U, Jacobsson H, Sundin A, Nygren P, Frödin JE, Glimelius B. Early prediction of response to first-line chemotherapy by sequential [18 F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009, 20:1057-1061. 10.1093/annonc/mdn744, 19164458.
23. Kim J, Choi S, Yi H, Lim J, Lee M, Hyun I, Kim C. Prediction of response to chemotherapy using sequential F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with metastatic colorectal cancer. J Clin Oncol 2007, 25(18S):2536. Annual Meeting Proceedings Part I.
24. Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart M, Flamen P. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol 2012 Jul, 23(7):1687-93.
25. Calvo FA, Domper M, Matute R, Martínez-Lázaro R, Arranz JA, Desco M, Alvarez E, Carreras JL. 18 F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004, 58:528-535. 10.1016/j.ijrobp.2003.09.058, 14751524.
26. Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, Gava M, Fanti S, Mariani G, Muzzio PC, Rubello D. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 2007, 34:1583-1593. 10.1007/s00259-007-0426-1, 17503039.
27. Romas N, Kilpatrick NW, Ntouroupi TG. Analysis of circulating tumour cells in prostate, colorectal and ovarian cancer using robotic microscopy [abstract]. J Clin Oncol 2008, 26. May 20 suppl; abstr 11084.
28. Meropol NJ, Cohen SJ, Iannotti N, Saidman BH, Sabbath KD, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Punt CJA. Circulating tumour cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer. J Clin Oncol 2007, 25(18S):4010. ASCO Annual Meeting Proceedings Part I. 2007.
29. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. J Clin Oncol 2008, 26(19):3213-3221. Circulating tumor cells, progression-free survival, and overall survival in metastatic colorectal cancer: A subgroup analysis of a large multicenter study, 10.1200/JCO.2007.15.8923, 18591556.
30. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumour cells to tumour response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221. 10.1200/JCO.2007.15.8923, 18591556.
31. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumour cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-91. 10.1056/NEJMoa040766, 15317891.
32. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumour cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218-4224. 10.1158/1078-0432.CCR-05-2821, 16857794.
33. Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, Goldhirsch A, Sandri MT. Variation of circulating tumour cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008, 19:891-897. 10.1093/annonc/mdm558, 18056915.
34. Uen YH, Lu CY, Tsai HL, Yu FJ, Huang MY, Cheng TL, Lin SR, Wang JY. Persistent presence of postoperative circulating tumour cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol 2008, 15:2120-2128. 10.1245/s10434-008-9961-7, 18481151.
35. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009, 458:719-724. 10.1038/nature07943, 2821689, 19360079.
36. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005, 102(45):16368-16373. 10.1073/pnas.0507904102, 1283450, 16258065.
37. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008, 20:504-511. 10.1016/j.coi.2008.05.007, 18573340.
38. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56:641-648. 10.1007/s00262-006-0225-8, 16960692.
39. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29:482-491. 10.1038/onc.2009.356, 19881547.
40. Monzo M, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, Martinez F, Moreno J, Hernandez R, Navarro-Vigo M. Single Nucleotide Polymorphisms in Nucleotide Excision Repair Genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first line oxaliplatin/fluoropyrimidine. Oncology 2007, 72:364-370. 10.1159/000113534, 18204222.
41. Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-Fluorouracyl-based chemotherapy. Clin Cancer Res 2004, 10:5880-5888. 10.1158/1078-0432.CCR-04-0169, 15355920.
42. Bosch TM, Meijerman I, Beijnene JH, Schellens JHM. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006, 45:253-285. 10.2165/00003088-200645030-00003, 16509759.
43. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ. Association between glutathione S-transferase P1, T1 and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002, 94:936-942. 10.1093/jnci/94.12.936, 12072547.
44. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964. 10.1126/science.1129139, 17008531.
45. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29:610-618. 10.1200/JCO.2010.30.5425, 21245428.
46. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666. 10.1056/NEJMoa051424, 16371631.
47. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27:5944-5951. 10.1200/JCO.2008.19.6147, 19858404.
48. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS. Controlled Trial of Fluorouracil and Low-dose Leucovorin Given for 6 months as postoperative Adjuvant Therapy for Colon Cancer. J Clin Oncol 1997, 15:246-250.
49. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, Twito D, Morton RF, Tschetter LK, Barlow JF. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989, 7:1447-1456.